High WHO/ISUP Grade And Unfavorable Architecture, Rather Than Typing Of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis

Chen Yang MD,* Brian Shuch, MD,† Harriet Kluger, MD, PhD,‡ Peter A. Humphrey, MD, PhD,* and Adebowale J. Adeniran, MD*


汇报人:马静

辅导老师: 马世荣 讲师




- 乳头状肾细胞癌(PRCC)最初是在1976年由 Mancilla-Jimenez等描述的,是第二大常见的 RCC类型
- 分为1型和2型
- 孤立或者多发
- 双侧和多灶在PRCC中更常见
- 淋巴结转移常见,肾静脉侵犯较ccRCC少见


| Renal cell tumours | |
|---------------------------------------------|---------|
| Clear cell renal cell carcinoma | 8310/3 |
| Multilocular cystic renal neoplasm of low | |
| malignant potential | 8316/1 |
| Papillary renal cell carcinoma | 8255/1 |
| Hereditary leiomyomatosis and renal | |
| cell carcinoma (HLRCC)-associated | |
| renal cell carcinoma | 8311/3* |
| Chromophobe renal cell carcinoma | 8317/3 |
| Collecting duct carcinoma | 8319/3 |
| Renal medullary carcinoma | 8510/3 |
| MiT Family translocation carcinomas | 8311/3 |
| Succinate dehydrogenase (SDH)-deficient | |
| renal carcinoma | 8312/3 |
| Mucinous tubular and spindle cell carcinoma | 8480/3 |
| Tubulocystic renal cell carcinoma | 8316/3 |
| Acquired cystic disease associated renal | - |
| cell carcinoma | 8316/3 |
| Clear cell papillary renal cell carcinoma | 8323/1 |
| Renal cell carcinoma, unclassified | 8312/3 |
| Papillary adenoma | 8260/0 |
| Oncocytoma | 8290/0 |
| Onocoytoma | 0200,0 |



 Type 1 PRCCs are composed mostly of small basophilic cuboidal cells arranged in a single layer. Cells tend to have a small, uniform, round to oval nuclei with inconspicuous nucleoli.



 In contrast, pseudostratified layers of cells with a copious amount of eosinophilic cytoplasm and atypical nuclei showing prominent nucleoli are the hallmark features of type 2 PRCCs.



巨噬细胞

巢团状


梁索状

囊性/腺样生长


PRCC的级别和亚型的比较

| 分型 | 1型 | 2型 |
|---------|-----------|---------|
| 级别 | 低级别 | 高级别 |
| ISUP核分级 | 1级和2级 | 3级和4级 |
| 大小 | /J\ | 大 |
| 基因学 | 低级别不同于高级别 | |
| 生物学行为 | 惰性 | 侵袭性 |
| 胞质 | 较少(似嗜碱) | 丰富,嗜酸性 |
| 泡沫细胞 | 常见 | 不太常见 |
| 细胞层数 | 单层 | 单层或假复层 |
| 核级别 | 常为低级别 | 常为高级别 |
| 生物学行为 | 绝大多是惰性 | 绝大多是侵袭性 |

免疫组织化学



免疫组织化学



分子检测

- 染色体7、17三倍体是最常见的细胞遗传学发现
- 家族性PRCC具有Met突变或延胡索酸水化酶基因的改变,散发性PRCC中这些基因的突变率非常低


- College of American Pathologists (CAP) guidelines require reporting the presence of WHO/ISUP grade, tumor necrosis, lymphovascular invasion (LVI), and rhabdoid or sarcomatoid histology have been well-esatablished to be associated with aggressive disease behavior.
- Other features, such as the presence of foamy macrophages, hemosiderin-laden macrophages, psammomatous calcification have also been proposed to have a prognostic impact.

- However, unfavorable histologic findings in tumors with papillary architecture from other anatomic sites have not been thoroughly evaluated in PRCCs.
- Specifically, solid and hobnail architecture are seen in papillary thyroid carcinoma, and the micropapillary architecture observed in urothelial carcinoma have not been described in the PRCC literature.
- The goal of our study was to evaluate the prognostic significance of PRCC typing,
 WHO/ISUP grade, and novel solid, micropapillary, and hobnail architecture in a large cohort of patients with clinical follow-up.

- The surgical pathology archives from the Department of Pathology were searched for partial and radical nephrectomies performed between the years 1996 and 2017 with the final or main differential diagnosis of PRCC.
- All archived hematoxylin and eosin and immunohistochemistry stained slides were retrieved and reviewed by 2 genitourinary pathologists blinded to the clinical outcome.

- A total of 185 cases were confirmed as PRCC and were included in our analysis.
 Clinical information and follow-up data were extracted from the electronic medical records.
- Primary tumor size and pathologic stage were recorded from the initial surgical pathology report.

- All slides were reviewed for the following features:
- type 1 versus type 2 histology;
- tumor grade (WHO/ISUP grading scheme);
- tumor necrosis;
- LVI;
- special architecture (solid, micropapillary, and hobnail);
- special cytology (oncocytoma-like cytologic features, papillary thyroid carcinoma-like nuclear features, clear/flocculent cytoplasm; hemosiderinrich cytoplasm);
- percentage of macrophages.








FIGURE 1. Morphologic spectrum seen in PRCC.


- strict definitions to classify the 3 special architectures (Fig. 2)
- for solid



- strict definitions to classify the 3 special architectures (Fig. 2)
- for micropapillary



- strict definitions to classify the 3 special architectures (Fig. 2)
- for hobnail architecture



• Relationships between the different variables were examined using Kruskal-Wallis tests, Mann-Whitney U tests, χ^2 tests, and Cox proportional hazards regression analyses.

Results—Clinical Characteristics

| TABLE 1. | Patient D | emographics | and Tumor | Characteristics |
|----------|-----------|-------------|-----------|-----------------|
| | | | | |

| Characteristics | Cases, n (%) |
|---------------------|--------------|
| Patients | |
| Male | 147 (79.5) |
| Female | 38 (20.5) |
| Age (y) | |
| Mean | 59 |
| Median | 60 |
| Range | 11-89 |
| Ethnicity | |
| White | 125 (67.6) |
| Black | 51 (27.6) |
| Other | 9 (4.9) |
| Laterality | |
| Left | 94 (50.8) |
| Right | 89 (48.1) |
| Bilateral | 1 (0.5) |
| Allograft | 1 (0.5) |
| Treatment | |
| Radical nephrectomy | 73 (39.5) |
| Partial nephrectomy | 112 (60.5) |

Results—Clinical Characteristics

| Tumor size (cm) | |
|-------------------------------|------------|
| Mean | 4.3 |
| Median | 3.5 |
| Range | 1.5-18.0 |
| Tumor type | |
| Type 1 | 117 (63.2) |
| Type 2 | 45 (24.3) |
| Mixed types 1 and 2 | 11 (5.9) |
| Other | 12 (6.5) |
| WHO/ISUP grade | |
| Grade 1 | 6 (3.2) |
| Grade 2 | 116 (62.7) |
| Grade 3 | 61 (33.0) |
| Grade 4 | 2 (1.1) |
| AJCC staging (eighth edition) | |
| Stage I | 152 (82.6) |
| Stage II | 20 (10.9) |
| Stage III | 12 (6.5) |
| Stage IV | 0 (0) |
| Follow-up (mo) | |
| Mean | 74 |
| Median | 59 |
| Range | 0.1-241 |
| Metastasis | |
| Yes | 11 (5.9) |
| No | 174 (94.1) |

Results—Histologic Characteristics

- Coagulative tumor necrosis was seen in 26 cases (14.1%)
- Sarcomatoid differentiation and LVI were seen only in 1 case (0.5%) each
- The solid architecture was observed in 3 cases (1.6%)
- Micropapillary architecture was present in 10 cases (5.4%)
- Hobnail architecture was seen in 9 cases (4.9%)
- Clear/flocculent cytoplasm was identified in 110 cases (59.5%)
- Hemosiderin was present in tumor cells in 60 cases (32.4%)
- Macrophages were also frequently seen, present in 125 cases (67.6%)
- 8 cases (4.3%) of OPRCC and 6 cases (3.2%) of PRCC demonstrating papillary thyroid carcinoma–like features (PTCPRCC) were identified

TABLE 2. Univariate Analysis of DFS and OS Prognostic Parameters

| | | DFS | | OS | | | | |
|----------------------------|-------|-------------|--------|------|-------------|--------|--|--|
| Prognostic Factors | HR | 95% CI | P | HR | 95% CI | P | | |
| Age (n) | | | | | | | | |
| < 60 y (90) | 1 | | | 1 | | | | |
| \geq 60 y (95) | 1.12 | 0.34-3.70 | 0.84 | 1.70 | 0.80 - 3.62 | 0.17 | | |
| Sex (n) | | | | | | | | |
| Female (38) | 1 | | | 1 | | | | |
| Male (147) | 0.64 | 0.17-2.42 | 0.51 | 0.84 | 0.34-2.06 | 0.70 | | |
| WHO/ISUP grade | 9.74 | 2.95-32.19 | < 0.01 | 4.07 | 2.01-8.21 | < 0.01 | | |
| AJCC stage | 5.45 | 2.76-1075 | < 0.01 | 3.03 | 1.98-4.62 | < 0.01 | | |
| (eighth edition) | | | | | | | | |
| Multifocality | | | | | | | | |
| Unifocal (169) | 1 | | | 1 | | | | |
| Multifocal (16) | 0.00 | 0.00 - 4.62 | 0.97 | 0.29 | 0.04-2.12 | 0.22 | | |
| Tumor size (n) | | | | | | | | |
| $< 4 \mathrm{cm} (107)$ | 1 | | | 1 | | | | |
| $\geq 4 \mathrm{cm} (78)$ | 14.92 | 1.91-116.66 | 0.01 | 2.99 | 1.39-6.45 | < 0.01 | | |

| | Solid (n) | | | | | | |
|---|----------------------|--------|------------|--------|-------|------------|--------|
| | No (182) | 1 | | | 1 | | |
| | Yes (3) | 20.56 | 4.25-99.44 | < 0.01 | 17.84 | 5.06-62.83 | < 0.01 |
| | Micropapillary (n) | | | | | | |
| | No (175) | 1 | | | 1 | | |
| | Yes (10) | 16.43 | 5.01-53.95 | < 0.01 | 5.23 | 2.12-12.88 | < 0.01 |
| | Hobnail (n) | | | | | | |
| | No (176) | 1 | | | 1 | | |
| | Yes (9) | 14.84 | 4.33-50.90 | < 0.01 | 4.03 | 1.40-11.61 | < 0.01 |
| ľ | Necrosis (n) | | | | | | |
| | No (159) | 1 | | | 1 | | |
| | Yes (26) | 2.68 | 0.71-10.12 | 0.15 | 3.68 | 1.67-8.12 | < 0.01 |
| | Clear/flocculent cyt | oplasn | n (n) | | | | |
| | No (75) | 1 | | | 1 | | |
| | Yes (110) | 1.85 | 0.49-6.98 | 0.36 | 1.17 | 0.55-2.47 | 0.69 |
| | Hemosiderin (n) | | | | | | |
| | No (125) | 1 | | | 1 | | |
| | Yes (60) | 1.27 | 0.37-4.36 | 0.70 | 1.68 | 0.80-3.54 | 0.17 |
| | Macrophages (n) | | | | | | |
| | No (60) | 1 | | | 1 | | |
| | Yes (125) | 0.53 | 0.16-1.73 | 0.29 | 0.56 | 0.27-1.18 | 0.13 |
| | PRCC subtype (n) | | | | | | |
| | Type 1 (117) | 1 | | | 1 | | |
| | Type 2 (45) | 1.14 | 0.29-4.43 | 0.85 | 1.12 | 0.46-2.69 | 0.80 |
| | Types 1 and 2 | 1.23 | 0.43-3.51 | 0.70 | 0.75 | 0.28-2.07 | 0.58 |
| | (11) | | | | | | |
| | | | | | | | |




FIGURE 3. Kaplan-Meier curves showing parameters affecting the DFS and OS of PRCC patients.

TABLE 3. Multivariate Analysis of DFS and OS Prognostic Parameters

| | | DFS | | | os | | |
|----------------------------------|------|-------------|--------|------|------------|--------|--|
| Prognostic Factors | HR | 95% CI | P | HR | 95% CI | P | |
| Age $(\geq 60 \text{ y})$ | 0.70 | 0.13-3.90 | 0.68 | 1.01 | 0.42-2.42 | 0.98 | |
| Sex (male) | 0.35 | 0.06-2.10 | 0.25 | 0.94 | 0.33-2.70 | 0.91 | |
| Tumor size $(\geq 4 \text{ cm})$ | 5.51 | 0.57-53.05 | 0.14 | 1.48 | 0.55-3.99 | 0.43 | |
| AJCC stage (eighth edition) | 4.39 | 1.55-11.84 | < 0.01 | 1.88 | 1.01-3.50 | < 0.05 | |
| Subtype (type 2) | 0.52 | 0.09-3.03 | 0.47 | 0.32 | 0.11-0.98 | < 0.05 | |
| WHO/ISUP grade | 7.00 | 1.52-32.20 | 0.01 | 5.08 | 2.09-12.36 | < 0.01 | |
| Solid | 2.59 | 0.07-90.69 | 0.60 | 2.48 | 0.29-20.98 | 0.41 | |
| Micropapillary | 6.30 | 0.75-52.65 | 0.09 | 4.21 | 1.15-15.45 | 0.03 | |
| Hobnail | 6.61 | 0.37-117.60 | 0.19 | 0.76 | 0.14-3.00 | 0.74 | |
| Necrosis | 0.48 | 0.03-6.65 | 0.58 | 2.15 | 0.70-6.58 | 0.18 | |
| Macrophages | 0.81 | 0.07-9.62 | 0.87 | 0.66 | 0.23-1.88 | 0.43 | |

Bold values indicate statistical significance.

CI indicates confidence interval; HR, hazard ratio.




FIGURE 4. Comparison of cases with and without recurrence/ metastasis.

- The classification of kidney epithelial neoplasms has undergone significant transformation in the past few decades.
- Our results in a large single-institutional study highlight histopathologic features relevant to prognosis in PRCCs. We identified WHO/ISUP grade and novel solid, micropapillary, and hobnail growth patterns, rather than PRCC type as being correlated with worse prognosis in our cohort of patients.

• We utilized the WHO/ISUP grading scheme in our study and showed that WHO/ISUP grade is the only other parameter, aside from the pathologic stage, to show statistical significance in predicting DFS and OS (Table 3). Of the 11 cases with metastatic disease, 8 (72.7%) were WHO/ISUP grade 3 and 4 PRCCs.

- Despite the major role of tumor architecture evaluation in the grading of many malignancies,
 scant data exist for unfavorable growth patterns in PRCCs.
- Given the resemblance in the histology of PRCC to papillary thyroid carcinoma, we hypothesized that these similar architectures might also carry a poor prognosis in PRCCs.
- We found that all 3 architectural patterns were associated with worse DFS and OS on univariate survival analysis (Table 2). Only micropapillary architecture was shown to be statistically significant as an adverse prognostic factor of OS in multivariate analysis (Table 3).

• Studies in the ""
var'



风险比率,正式的英文名称是Hazard Ratio。风险比率是两个风险率(Hazard Rate)

_的比值。它反映了单位时间内的相对风险,是相对风险在单位时间内的一种反映。

with u rauos (Hks,

gic studies

Jon DFS and OS, respectively.

| A | F 5. 8_ U.S | | | Hazard Ratio | | | ard Ratio | |
|----------------------------|------------------------------|-----------|----------|----------------------|------|-------------|------------|----------|
| Study or Subgroup | log[Hazard Ratio] | SE | Weight | IV, Random, 95% CI | Year | IV, Ran | dom, 95% C | <u> </u> |
| Pignot et al. (2007) | 1.1694 | 0.5527 | 18.0% | 3.22 [1.09, 9.51] | 2007 | | - | |
| Ku et al. (2009) | 0.9888 | 0.8151 | 11.6% | 2.69 [0.54, 13.28] | 2009 | | - | |
| Klatte et al. (2009) | -0.3567 | 0.6143 | 16.2% | 0.70 [0.21, 2.33] | 2009 | _ | • | |
| Hutterer et al. (2013) | -0.2107 | 0.3231 | 26.0% | 0.81 [0.43, 1.53] | 2013 | | • | |
| Cornejo et al. (2015) | 1.1939 | 0.5605 | 17.8% | 3.30 [1.10, 9.90] | 2015 | | - | |
| Current study | -0.6539 | 0.8949 | 10.3% | 0.52 [0.09, 3.00] | 2019 | _ | - | |
| Total (95% CI) | | | 100.0% | 1.43 [0.73, 2.80] | | | • | |
| Heterogeneity: $Tau^2 = 0$ | 0.35 ; $Chi^2 = 10.45$, (| df = 5 (P | = 0.06); | l ² = 52% | - | - | + + | |
| Test for overall effect: Z | | | | | 0.00 | 0.1 | 1 10 | 1000 |
| | | | | | | Type 1 PRCC | Туре | 2 PRCC |

| 3 | | | | Hazard Ratio | | Hazar | d Ratio | |
|-------------------------------------|--------------------------------|----------|----------|---------------------|-------|-------------|-----------|--------|
| Study or Subgroup | log[Hazard Ratio] | SE | Weight | IV, Random, 95% CI | Year | IV, Rando | m, 95% CI | |
| Delahunt et al. (2001) | 0.6366 | 0.62 | 8.5% | 1.89 [0.56, 6.37] | 2001 | - | - | |
| Allory et al. (2003) | 1.4609 | 0.4225 | 12.6% | 4.31 [1.88, 9.86] | 2003 | | - | |
| Klatte et al. (2010) | -0.1393 | 0.597 | 8.9% | 0.87 [0.27, 2.80] | 2010 | | - | |
| Sukov et al. (2012) | -0.1508 | 0.3419 | 14.6% | 0.86 [0.44, 1.68] | 2012 | _ | - | |
| Pichler et al. (2012) | 0.1823 | 0.275 | 16.5% | 1.20 [0.70, 2.06] | 2013 | (- | • | |
| Cornejo et al. (2015) | 0.5306 | 0.3245 | 15.1% | 1.70 [0.90, 3.21] | 2015 | | • | |
| Polifka et al. (2018) | -0.0619 | 0.368 | 13.9% | 0.94 [0.46, 1.93] | 2018 | - | - | |
| Current study | -1.1394 | 0.5448 | 9.9% | 0.32 [0.11, 0.93] | 2019 | - | 1 | |
| Total (95% CI) | | | 100.0% | 1.21 [0.77, 1.91] | | | • | |
| Heterogeneity: Tau ² = (| 0.26 ; $Chi^2 = 18.36$, c | f = 7 (P | = 0.01); | 2 = 62% | - | | + | |
| Test for overall effect: 2 | | - 5 | | | 0.001 | 0.1 | 1 10 | 1000 |
| | | | | | | Type 1 PRCC | Type | 2 PRCC |

FIGURE 5. Forest plot comparing the HR of reports in the literature of type 2 versus type 1 PRCC in predicting DFS (A) and OS (B), respectively.

OPRCC oncocytic papillary renal cell carcinoma(嗜酸性乳头状肾细胞癌)




FIGURE 6. PRCCs with special cytologic features.

PTCRCC papillary thyroid carcinoma—like features RCC (甲状腺乳头状癌样特征的RCC)




FIGURE 6. PRCCs with special cytologic features.

ESCRCC eosinophilic solid and cystic renal cell carcinoma(嗜酸性实性和囊性肾细胞癌)




FIGURE 6. PRCCs with special cytologic features.

- First, our study was retrospective in design and was limited by the inherent bias associated with any investigation of this nature.
- Second, all our cases originated from a single institution and was inevitably influenced by the patient population represented in this geographic region.
- Third, our study has a limited number of cases with special histology (solid, micropapillary, and hobnail) due to the relatively low prevalence. A prospective and large multi-institutional study would be necessary to address the above issues.
- Finally, the low number of progression events (metastasis) is a limitation of this study in the multivariate analysis, but this is a reflection of the relatively indolent nature of PRCC.

- The architecture of clear cell RCC has recently been shown to be of prognostic significance.
- The analysis presented here is the first to comprehensively evaluate WHO/ISUP grade and new histopathologic (micropapillary, hobnail, or solid) architectures in a large cohort of PRCCs.

- Parameters associated with worse DFS and OS in the univariate analysis included WHO/ISUP grade, pathologic stage, tumor size, and solid, micropapillary, or hobnail architecture.
- On multivariate analysis, tumor pathologic stage and WHO/ISUP grade, and not PRCC type, show statistically significant association with DFS and OS.
- These unfavorable features should be documented on routine histologic evaluation to provide additional information to help physicians to better risk-stratify patients for therapy or surveillance.

